General Information of Drug Therapeutic Target (DTT) (ID: TT9JZCK)

DTT Name Sphingosine-1-phosphate receptor 1 (S1PR1)
Synonyms Sphingosine 1-phosphate receptor Edg-1; S1P1; S1P receptor Edg-1; S1P receptor 1; Endothelial differentiation G-protein coupled receptor 1; CHEDG1; CD363
Gene Name S1PR1
DTT Type
Successful target
[1]
BioChemical Class
GPCR rhodopsin
UniProt ID
S1PR1_HUMAN
TTD ID
T13852
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISADKENSIKLTSVVFILICCFII
LENIFVLLTIWKTKKFHRPMYYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLR
EGSMFVALSASVFSLLAIAIERYITMLKMKLHNGSNNFRLFLLISACWVISLILGGLPIM
GWNCISALSSCSTVLPLYHKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKN
ISKASRSSEKSLALLKTVIIVLSVFIACWAPLFILLLLDVGCKVKTCDILFRAEYFLVLA
VLNSGTNPIIYTLTNKEMRRAFIRIMSCCKCPSGDSAGKFKRPIIAGMEFSRSKSDNSSH
PQKDEGDNPETIMSSGNVNSSS
Function
Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. Plays an important role in cell migration, probably via its role in the reorganization of the actin cytoskeleton and the formation of lamellipodia in response to stimuli that increase the activity of the sphingosine kinase SPHK1. Required for normal chemotaxis toward sphingosine 1-phosphate. Required for normal embryonic heart development and normal cardiac morphogenesis. Plays an important role in the regulation of sprouting angiogenesis and vascular maturation. Inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. Required for normal egress of mature T-cells from the thymus into the blood stream and into peripheral lymphoid organs. Plays a role in the migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis. Plays a role in responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine by pulmonary endothelial cells and in the protection against ventilator-induced lung injury. G-protein coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins.
KEGG Pathway
FoxO signaling pathway (hsa04068 )
Sphingolipid signaling pathway (hsa04071 )
Neuroactive ligand-receptor interaction (hsa04080 )
Reactome Pathway
Lysosphingolipid and LPA receptors (R-HSA-419408 )
G alpha (i) signalling events (R-HSA-418594 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [2]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [1]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [3]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [4]
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [5]
------------------------------------------------------------------------------------
12 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [6]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [7]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [8]
ONO-4641 DMLUM3Y Rheumatoid arthritis FA20 Phase 2 [7]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [9]
ASP-4058 DM1RD0T Multiple sclerosis 8A40 Phase 1 [10]
BMS-986104 DMZ4WMT Rheumatoid arthritis FA20 Phase 1 [2]
CS-0777 DMG0SPO Multiple sclerosis 8A40 Phase 1 [11]
GSK-2018682 DMRU4YV Immune System disease 4A01-4B41 Phase 1 [7]
SAR247799 DMUAJZD Cardiovascular disease BA00-BE2Z Phase 1 [12]
Sonepcizumab DMB3YZJ Macular degeneration 9B78.3 Phase 1 [7]
Sphingosine-1-phosphate DMJCQKA Acne vulgaris ED80 Phase 1 [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Clinical Trial Drug(s)
2 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-4629991 DMNLAU7 Rheumatoid arthritis FA20 Discontinued in Phase 1 [14]
XL-541 DM965P4 Solid tumour/cancer 2A00-2F9Z Terminated [15]
------------------------------------------------------------------------------------
32 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(3-Tetradecylamino-cyclohexyl)-phosphonic acid DM6P35D Discovery agent N.A. Investigative [16]
(3-Tetradecylamino-cyclopentyl)-phosphonic acid DMFMBPT Discovery agent N.A. Investigative [16]
(S)-FTY720P DM5WETL N. A. N. A. Investigative [17]
1-(4-nonylbenzyl)azetidine-3-carboxylic acid DMQKMCG Discovery agent N.A. Investigative [18]
1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid DM8U2HP Discovery agent N.A. Investigative [18]
1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid DMAR39L Discovery agent N.A. Investigative [18]
3-(N-alkylamino) propylphosphonic acid derivative DMJDG9C Discovery agent N.A. Investigative [16]
3-(tetradecylamino)propylphosphonic acid DMNA6LF Discovery agent N.A. Investigative [18]
3-amino-5-(4-octylphenyl)pentanoic acid DMONHFR Discovery agent N.A. Investigative [19]
4-amino-6-(4-octylphenyl)hexanoic acid DMZRM0Q Discovery agent N.A. Investigative [19]
AFD(R) DME9Y8Q Discovery agent N.A. Investigative [20]
AMG-247 DMU6WR9 Inflammation 1A00-CA43.1 Investigative [21]
AUY954 DMVGIO5 Discovery agent N.A. Investigative [22]
BMS-520 DMAY9TM Immune System disease 4A01-4B41 Investigative [21]
CYM5181 DMGTZ9Q Discovery agent N.A. Investigative [23]
CYM5442 DMURD2E Discovery agent N.A. Investigative [23]
FTY720-phosphate DMDZBQH Discovery agent N.A. Investigative [20]
GNF-PF-78 DM7SPRJ Discovery agent N.A. Investigative [24]
GNF-PF-826 DM37ORC Discovery agent N.A. Investigative [24]
GSK-1842799C DM2KT17 Cardiovascular disease BA00-BE2Z Investigative [21]
KRP 203-phosphate DMLIK7X Discovery agent N.A. Investigative [25]
KRP-107 DM5KFBP Autoimmune diabetes 5A10 Investigative [21]
LPA DMI5XR1 Discovery agent N.A. Investigative [26]
NIBR-0213 DMH6MVJ Discovery agent N.A. Investigative [27]
NIBR-785 DMU0BMQ Multiple sclerosis 8A40 Investigative [21]
NOX-S91 DMVS6DW Solid tumour/cancer 2A00-2F9Z Investigative [21]
SEW2871 DMJBW7X Discovery agent N.A. Investigative [28]
VPC03090-P DMIXUM3 Discovery agent N.A. Investigative [29]
VPC23019 DMVQFY4 Discovery agent N.A. Investigative [30]
VPC44116 DMQ4OTJ Discovery agent N.A. Investigative [31]
W146 DMDYTSW Discovery agent N.A. Investigative [32]
[3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid DMGD487 Discovery agent N.A. Investigative [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Psoriasis EA90 Skin 7.89E-08 -0.26 -0.5
Lung cancer 2C82 Lung tissue 1.41E-119 -2.24 -3.66
Rheumatoid arthritis FA20 Synovial tissue 3.68E-03 -0.06 -0.15
------------------------------------------------------------------------------------

References

1 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6 Clinical pipeline report, company report or official report of Connect Biopharma
7 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
8 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
9 Clinical pipeline report, company report or official report of Ventyx Biosciences
10 ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
11 Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.
14 US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
15 Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J Med Chem. 2012 Feb 9;55(3):1368-81.
16 Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6.
17 Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009 Jun;5(6):428-34.
18 A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5.
19 S1P receptor mediated activity of FTY720 phosphate mimics. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1485-7.
20 The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
22 A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
23 Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18.
24 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
25 A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83.
26 Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem. 1998 Aug 21;273(34):22105-12.
27 A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol. 2012 Sep 21;19(9):1142-51.
28 Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
29 Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
30 Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005 Mar 18;280(11):9833-41.
31 Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
32 Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006 Aug;2(8):434-41.